| Literature DB >> 34193597 |
William E Matchett1,2, Vineet Joag1,2, J Michael Stolley1,2, Frances K Shepherd1,2, Clare F Quarnstrom1,2, Clayton K Mickelson1, Sathi Wijeyesinghe1,2, Andrew G Soerens1,2, Samuel Becker1,2, Joshua M Thiede2,3, Eyob Weyu1,2, Stephen D O'Flanagan1,2, Jennifer A Walter1,2, Michelle N Vu4, Vineet D Menachery4, Tyler D Bold2,3, Vaiva Vezys1,2, Marc K Jenkins5,2, Ryan A Langlois5,2, David Masopust5,2.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34193597 PMCID： PMC8516699 DOI： 10.4049/jimmunol.2100421
Source DB: PubMed Journal: J Immunol ISSN： 0022-1767 Impact factor: 5.426